SCHEMBL5537652

SCHEMBL5537652

Cc1c([O])ccc2c1CC(C)(C)O2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.39
ALDH1A1 P00352 8/20 0.36
KDM4E B2RXH2 6/20 0.36
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
FFAR4 Q5NUL3 1/20 0.32
GAA P10253 5/20 0.32
HPGD P15428 5/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
HSD17B10 Q99714 3/20 0.32
CASP1 P29466 2/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
GLA P06280 2/20 0.32
CASP7 P55210 1/20 0.32
TP53 P04637 3/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
MAOB P27338 1/20 0.31
CCR8 P51685 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5537657 0.78 MAPT (0.42) MAPTALDH1A1KDM4EMTNR1AMTNR1B
SCHEMBL14113160 0.70 MAPT (0.42) MAPTALDH1A1KDM4EMTNR1AMTNR1B
SCHEMBL8633979 0.69 ALDH1A1 (0.34) MAPTALDH1A1KDM4ESMN1; SMN2
SCHEMBL12180437 0.69 ALDH1A1 (0.40) MAPTALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL5584611 0.68 MTNR1A (0.32) MAPTMTNR1AMTNR1B
SCHEMBL6737407 0.68 AKT1 (0.44) MAPTALDH1A1KDM4EMTNR1AMTNR1B
SCHEMBL658523 0.66 ALDH1A1 (0.32) MAPTALDH1A1KDM4E
SCHEMBL3592511 0.66 ALDH1A1 (0.32) MAPTALDH1A1KDM4ETP53
SCHEMBL18029940 0.66 KDM4E (0.46) MAPTALDH1A1KDM4EGAAHPGD
SCHEMBL6130778 0.66 ALDH1A1 (0.38) MAPTALDH1A1KDM4EGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885ALDH1A1 355/4885KDM4E 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.